相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France
Sandra Vukusic et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder
Amy Kunchok et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
The MSBase registry: Informing clinical practice
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
J. William L. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1
Anthony Traboulsee et al.
BMC NEUROLOGY (2018)
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Nathaniel Lizak et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Marcus D'Souza et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Marcus D'Souza et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Data quality evaluation for observational multiple sclerosis registries
Tomas Kalincik et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
Jan-Patrick Stellmann et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J. Coles et al.
NEUROLOGY (2017)
Autologous hematopoietic stem cell transplantation in multiple sclerosis A meta-analysis
Maria Pia Sormani et al.
NEUROLOGY (2017)
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation
Katy Wright et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
Ludwig Kapposl et al.
JOURNAL OF NEUROLOGY (2016)
Brain health: time matters in multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Defining reliable disability outcomes in multiple sclerosis
Tomas Kalincik et al.
BRAIN (2015)
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
L. Kappos et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
EVIDENCE-BASED GUIDELINES MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients
Mike P. Wattjes et al.
NATURE REVIEWS NEUROLOGY (2015)
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Orla Tuohy et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
Ludwig Kappos et al.
JOURNAL OF NEUROLOGY (2013)
Clinical Pharmacokinetics of Fingolimod
Olivier J. David et al.
CLINICAL PHARMACOKINETICS (2012)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Real-Life Impact of Early Interferonβ Therapy in Relapsing Multiple Sclerosis
M. Trojano et al.
ANNALS OF NEUROLOGY (2009)
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
Emmanuelle Le Page et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
MSBase:: an international, online registry and platform for collaborative outcomes research in multiple sclerosis
H. Butzkueven et al.
MULTIPLE SCLEROSIS (2006)
Analytical identification of ideal pulmonary-systemic flow balance in patients with bidirectional cavopulmonary shunt and univentricular circulation - Oxygen delivery or tissue oxygenation?
Gerhard-Paul Diller et al.
CIRCULATION (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Kurtzke scales revisited: the application of psychometric methods to clinical intuition
J Hobart et al.
BRAIN (2000)
分享论文
